Immunome's total assets for Q4 2025 were $683.19M, an increase of 128.20% from the previous quarter. IMNM total liabilities were $48.84M for the fiscal quarter, a 37.75% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.